0000950170-24-076380.txt : 20240621 0000950170-24-076380.hdr.sgml : 20240621 20240621180015 ACCESSION NUMBER: 0000950170-24-076380 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240618 FILED AS OF DATE: 20240621 DATE AS OF CHANGE: 20240621 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: VAN NOSTRAND ROBERT L CENTRAL INDEX KEY: 0001225198 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 241061589 MAIL ADDRESS: STREET 1: C/O ACHILLION PHARMACEUTICALS, INC. STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 ownership.xml 4 X0508 4 2024-06-18 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001225198 VAN NOSTRAND ROBERT L C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET NEW YORK NY 10016 true false false false true Common Stock 2024-06-18 4 M false 20000 16.86 A 29690 D Common Stock 2024-06-18 4 S false 8891 75.71 D 20799 D Common Stock 2024-06-18 4 S false 11109 76.07 D 9690 D Stock Option (right to buy) 16.86 2024-06-18 4 M false 20000 0.00 D 2024-06-30 Common Stock 20000 0 D On June 18, 2024, the reporting person exercised options to purchase 20,000 shares of common stock that are expiring on June 30, 2024. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.01 to $76.00, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.01 to $76.09, inclusive. The reporting person undertakes to provide to the Issuer, any secuirty holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. This option was granted on June 30, 2014 and will expire on June 30, 2024. All shares underlying this option have vested. /s/ Lawrence J. Hineline, Attorney-in-fact 2024-06-21